Overview

Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation

Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether 3 cycles of chemotherapy(CEV) are as effective as 6 cycles of chemotherapy(CEV) in the treatment of Stage I enucleated retinoblastoma.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborator:
Fudan University
Treatments:
Carboplatin
Etoposide
Etoposide phosphate
Vincristine